1. Hardy JG, Chadwick TS. Sustained release drug delivery to the lungs: an option for the future. Clin Pharmacokinet 39(1):1-4, 2000.

2. Lewis AJ, et al. The comparative bronchodilator properties of alkyl quaternary salts of promethazine. Int Arch Allergy Appl Immunol 75(3): 282-283, 1984.

3. Scherer PW, et al. Growth of hygroscopic aerosols in a model of bronchial airways. J Appl Physiol 47(3):544-550, 1979.

Sciarra JJ, Patel JM, Kapoor AL. Synthetics and formulation of several epinephrine salts as an aerosl dosage form. J Pharm Sci 61(2):219-223, 1972. Chowhan ZT, Amaro AA. Pulmonary absorption studies utilizing in situ rat lung model: designing dosage regimen for bronchial delivery of new drug entities. J Pharm Sci 65(11):1669-1672, 1976.

Hickey AJ, Byon PR. Preparation characterization, and controlled release from coprecipitates of fluorescein and magnesiumhydroxide. J Pharm Sci 75(8):756-759, 1986.

Hickey AJ, Jackson GV, Fildes FJ. Preparation and characterization of disodium fluorescein powders in association with lauric and capric acids. J Pharm Sci 77(9):804-809, 1988.

Niven RW, Byron PR. Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract. Pharm Res 5(9):574-579, 1988.

Wurster DE. Will the Pharm.D. make the pharmaceutics Ph.D. an endangered species? Pharm Dev Technol 2(1):vii-viii, 1997.

Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 48(1):27 -42, 2001.

Blomberg E, Claesson PM, Froberg JC. Surfaces coated with protein layers: a surface force and ESCA study. Biomaterials 19(4-5):371-386, 1998. Desai TR, et al. Determination of surface free energy of interactive dry powder liposome formulations using capillary penetration technique. Colloids Surf B Biointerfaces 22(2):107-113, 2001.

Bottom R. The role of modulated temperature differential scanning calorimetry in the characterization of a drug molecule exhibiting polymorphic and glass forming tendencies. Int J Pharm 192(1):47-53, 1999.

Newell HE, et al. The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallization. Int J Pharm 217(1-2):45-56, 2001. Rabel SR, Jona JA, Maurin MB. Applications of modulated differential scanning calorimetry in performulation studies. J Pharm Biomed Anal 21(2):339-345, 1999. Buckton G. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv Drug Deliv Rev 26(1):17-27, 1997.

Masters K. Spray Drying Handbook. 5th ed. New York: Halsted Press, 725, 1991. Christensen KL, Pedersen GP, Kristensen HG. Preparation of redispersible dry emulsions by spray drying. Int J Pharm 212(2):187-194, 2001. Maa YF, et al. Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res 16(2):249-254, 1999.

Palakodaty S, York P, Pritchard J. Supercritical fluid processing of materials from aqueous solutions: the applications of SEDS to lactose as a model substance. Pharma Res 15(12):1835-1843, 1998.

York P. Strategies for particle design using supercritical fluid technologies. Pharm Sci Technol Today 2(11):430-440, 1999.

Constantine HR, et al. Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 17(11):1374-1383, 2000.

Vanbever R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16(11):1735-1742, 1999.

Bain DF, Monday DL, Smith A. Solvent influence on spray-dried biodegradable microspheres. J Microencapsulate 16(4):453-474, 1999.

Maa YF, et al. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol 2(3):213-223, 1997. Dunbar CA, Concession NM, Hickey AJ. Evaluation of atomizer performance in production of respirable spray-dried particles. Pharm Dev Technol 3(4):433-441, 1998.

Ben-Jebria A, et al. Large porous particles for sustained protection form carbochol-induced bronchoconstriction in guinea pigs. Pharm Res 16(4):555-561, 1999. Kieswetter K, et al. Characterization of calcium phosphate powders by ESCA and EDXA. Biomaterials 15(3):183-188, 1994.

Millqvist-Fureby A, Malmsten M, Bergenstahl B. Spray-drying of trypsin—surface characterization and activity preservation. Int J Pharm 188(2):243-253, 1999. Millqvish-Fureby A, Malmsten M, Bergenstahl B. An aqueous polymer two-phase system as carrier in the spray-drying of biological material. J Colloid Interface Sci 225(1)54-61, 2000.

Adler M, Unger M, Lee G. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm Res 17(7):863-870, 2000. Tee SK, et al. The use of different sugars as fine and coarse carriers for aerosolized salbutamol sulphate. Int J Pharm 208(1-2):111-123, 2000.

Zeng XM, et al. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 200(1):93-106, 2000.

Bosquillon C, et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 70(3):329-339, 2001.

de Villiers MM. Influence of cohesive properties of micronized drug powders on particle size analysis. J Pharm Biomed Anal 13(3):191 -198, 1995. Fults KA, Miller IF, Hickey AJ. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol 19952(1):67-79, 1995.

Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 45(6):652-666, 2000.

Pharm S, Wiedmann TS. Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant. J Pharm Sci 90(1):98-104, 2001. Porter SC. Coating of pharmaceutical dosage forms. In: Remington: The Science and Practice of Pharmacy, Gennaro AR, ed. Lippincot Williams & Wilkins: Philadelphia, 2000, pp. 894-902.

Pillai RS, et al. Controlled dissolution from wax-coated aerosol particles in canine lungs. J Appl Physiol 84(2):717-725, 1998.

Hickey AJ, et al. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 79(11):1009-1014, 1990.

Hickey AJ, Martonen TB. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res 10(1):1 —7, 1993. Meisner D, Pringle J, Mezei M. Liposomal pulmonary drug delivery. I. In vivo disposition of atropine base in solution and liposomal form following endotracheal instillation to the rabbit lung. J Microencapsul 6(3):379-387, 1989. Jurima-Romet M, Shek PN. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J Pharm Pharmacol 43(1):6-10, 1991. McCalden TA, Porter J, Kamarei A. Aerosol delivery of lipsomes metaproternol sulfate. Pro West Pharmacol Soc 33, 171-173, 1990.

Forsgren P, et al. Intrapulmonary deposition of aerosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS. Ups J Med Sci 95(2):117-136, 1990.

Fielding RM. The use of inhaled liposome formulations for drug delivery to the lungs and systemic circulation. Proc West Pharmacol Soc 32, 103-106, 1989. Scheule RK, Cheng SH. Airway delivery of cationic lipid: DNA complexes for cystic fibrosis. Adv Drug Deliv Rev 30(1-3):173-184, 1998. Eastman SJ, et al. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid: DNA complex. Hum Gene Ther 8(3):313-322, 1997.

McDonald RJ, et al. Aerosol delivery of lipd:DNA complexes to lungs of rhesus monkeys. Pharm Res 15(5):671-679, 1998.

Stribling R, et al. Aerosol gene delivery in vivo. Proc Natl Acad Sci USA 89(23):11277-11281, 1992.

Gilbert BE, et al. Small particle aerosols of enviroxime-containing lipsomes. Antiviral Res 9(6):355-365, 1988.

Niven RW, Schreier H. Nebulization of liposomes. I. Effect of lipid composition. Pharm Res 7(11):1127-1133, 1990.

Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res 8(2):217-221, 1991. Niven RW, Carvajal TM, Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res 9(4):515-520, 1991. Zou Y, Priebe W, Perz-Soler R. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline anamycin: effect of surfactant on liposome formation, stability and size. Cancer Chemother Pharmacol 39(1-2):103-108, 1996. Skalko-Basnet N, Pavelin Z, Becirevic-Lacan M. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev Ind Pharm 26(12):1279-1284, 2000.

Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 7(1):33-41, 1999.

Schreier H, Hickey AJ, Niven RW. Formulation and in vitro performance of liposome powder aerosols. STP Pharma 4, 1-3, 1994.

Myers MA, et al. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp Lung Res 19(1):1-19, 1993.

Thomas DA, et al. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99(5):1268-1270, 1991.

Vyas SP, Sakthivel T. Pressurized pack-based liposomes for pulmonary targeting of isoprenaline—development and characterization. J Microencapsul 11(4):373-380,

Coping with Asthma

Coping with Asthma

If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.

Get My Free Ebook

Post a comment